Jen Kruger1, Alan Brennan. 1. School of Health and Related Research, University of Sheffield, Regent Court, 30 Regent Street, Sheffield, S1 4DA, UK, j.kruger@sheffield.ac.uk.
Abstract
AIMS: To identify cost-of-illness studies of Type 1 diabetes mellitus (Type 1 DM) in the United Kingdom (UK) and review this literature to estimate the current cost of Type 1 DM to the UK National Health Service. METHODS: Bibliographic databases and grey literature were searched systematically to identify all published and unpublished reporting of the costs of Type 1 DM in the UK. Studies were excluded if they did not present cost information from the UK or did not disaggregate information by diabetes type. Three grey literature sources and 11 published studies were identified for inclusion in the literature review. RESULTS: The included studies and reports covered topics including the overall cost of Type 1 DM, costs of individual diabetic complications and costs of specific interventions for Type 1 DM. The most recent published estimate of the cost of Type 1 DM was over 15 years old, and although this estimate has been inflated to current prices the estimate is not adjusted for changes to treatment pathways over this period and is therefore not considered an accurate estimate of current costs of Type 1 DM. CONCLUSIONS: There is no recently published estimate of the cost of Type 1 DM in the UK; therefore, it is recommended that an up-to-date national, comprehensive cost-of-illness study should be conducted. Recommendations for the format of this study are made, including extending the scope to cover recent treatment developments and resource use where diabetes is a subsidiary diagnosis.
AIMS: To identify cost-of-illness studies of Type 1 diabetes mellitus (Type 1 DM) in the United Kingdom (UK) and review this literature to estimate the current cost of Type 1 DM to the UK National Health Service. METHODS: Bibliographic databases and grey literature were searched systematically to identify all published and unpublished reporting of the costs of Type 1 DM in the UK. Studies were excluded if they did not present cost information from the UK or did not disaggregate information by diabetes type. Three grey literature sources and 11 published studies were identified for inclusion in the literature review. RESULTS: The included studies and reports covered topics including the overall cost of Type 1 DM, costs of individual diabetic complications and costs of specific interventions for Type 1 DM. The most recent published estimate of the cost of Type 1 DM was over 15 years old, and although this estimate has been inflated to current prices the estimate is not adjusted for changes to treatment pathways over this period and is therefore not considered an accurate estimate of current costs of Type 1 DM. CONCLUSIONS: There is no recently published estimate of the cost of Type 1 DM in the UK; therefore, it is recommended that an up-to-date national, comprehensive cost-of-illness study should be conducted. Recommendations for the format of this study are made, including extending the scope to cover recent treatment developments and resource use where diabetes is a subsidiary diagnosis.
Authors: C J Currie; C D Poole; A Woehl; C Ll Morgan; S Cawley; M D Rousculp; M T Covington; J R Peters Journal: Diabet Med Date: 2007-02 Impact factor: 4.359
Authors: S de Lusignan; K Khunti; J Belsey; A Hattersley; J van Vlymen; H Gallagher; C Millett; N J Hague; C Tomson; K Harris; A Majeed Journal: Diabet Med Date: 2010-02 Impact factor: 4.359
Authors: Simon de Lusignan; Hugh Gallagher; Tom Chan; Nicki Thomas; Jeremy van Vlymen; Michael Nation; Neerja Jain; Aumran Tahir; Elizabeth du Bois; Iain Crinson; Nigel Hague; Fiona Reid; Kevin Harris Journal: Implement Sci Date: 2009-07-14 Impact factor: 7.327